Hambach Lothar, Goulmy Els
Department of Immunohaematology and Bloodtransfusion, Leiden University Medical Center, Post Box 9600, 2300 RC Leiden, The Netherlands.
Curr Opin Immunol. 2005 Apr;17(2):202-10. doi: 10.1016/j.coi.2005.01.010.
Minor histocompatibility antigens are allogeneic targets of T-cell mediated graft-versus-tumour effects following allogeneic stem cell transplantation. Recent research has identified several minor histocompatibility antigens as tumour proteins and has also disclosed their unique properties in both the induction and the effector phase of graft-versus-tumour effects. Targeting tumour-specific minor histocompatibility antigens by adoptive immunotherapy will battle against tumour tolerance and evoke allo-immune responses, thereby enhancing graft-versus-tumour effects against leukaemia and solid tumours. Recently acquired knowledge of the role of donor immunisation status, new techniques in the generation of minor histocompatibility antigen-specific cytotoxic T lymphocytes in vitro, and innovative principles in vaccination will help to design clinical trials that exploit minor histocompatibility antigens in the immunotherapy of cancer.
微小组织相容性抗原是同种异体干细胞移植后T细胞介导的移植物抗肿瘤效应的同种异体靶标。最近的研究已将几种微小组织相容性抗原鉴定为肿瘤蛋白，并揭示了它们在移植物抗肿瘤效应的诱导期和效应期的独特特性。通过过继性免疫疗法靶向肿瘤特异性微小组织相容性抗原将对抗肿瘤耐受性并引发同种免疫反应，从而增强针对白血病和实体瘤的移植物抗肿瘤效应。最近获得的关于供体免疫状态作用的知识、体外产生微小组织相容性抗原特异性细胞毒性T淋巴细胞的新技术以及疫苗接种的创新原则将有助于设计在癌症免疫治疗中利用微小组织相容性抗原的临床试验。
